Clinical trials: HCV
HCV Infection
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of multiple doses of an experimental hepatitis C virus (HCV) protease inhibitor with ritonavir in healthy volunteers.
- Trial name
- NCT00931281
- Testing
- ABT-450, ritonavir
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Abbott
Chronic HCV Hepatitis C
A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.
Erstes Safety Trial mit Baminercept in chronischen HCV Patienten. Untersuchung des potentiell antiviralen, antiinflammatorischen Effekts sowie Modulation der hepatischen Gen-Expression.
- Trial name
- NCT01164384
- Testing
- Baminercept
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Zurich
HCV
TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers
The purpose of this study is to evaluate the safety and tolerability of three different doses of TMC435350 compared to placebo in healthy Japanese males.
- Trial name
- NCT00752544
- Testing
- TMC435350
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, HCV
TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule
The objectives are: to compare the oral bioavailability and plasma pharmacokinetics of TMC435350 for 2 different solid formulations to those of TMC435350 formulated as a powder blend in a capsule, after a single oral dose of 200…
- Trial name
- NCT00752648
- Testing
- TMC435350
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HCV Infection
Metabolic Viral Host Properties
Patients' metabolic properties may affect their immune response. This study aims to assess the effect of hosts' metabolic properties to viral infection.
- Trial name
- NCT00893308
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
HCV
Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects
This is a phase 1 study to assess the routes of elimination of a single oral dose of [14C] PF-00868554 and to characterize the metabolic profile following single dose administration.
- Trial name
- NCT00823745
- Testing
- [14C]-PF-00868554
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Pfizer